HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel ...
Gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. While ...
Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV ...
HOLLISTER, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...
Pharmaron Biologics, Liverpool, UK, is a commercial development and manufacturing organization (CDMO) that offers a range of unique end-to-end laboratory services for the development and manufacture ...
VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...
Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback